{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
l-glutamine
to a specific field?
Status:
Investigational
Source:
NCT01168752: Phase 1 Interventional Completed Cancer
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
CUDC-305, is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents. In both laboratory and animal testing, CUDC-305 demonstrated high potency in vitro and/or in vivo across a wide range of cancers. Most notably, Curis scientists observed complete tumor regression following oral administration of CUDC-305 in a mouse xenograft model of acute myelogenous leukemia (AML). Tumor regression has also been observed after treatment of CUDC-305 in mouse xenograft models of breast, non-small cell lung, gastric cancer and glioblastoma brain cancers. In this preclinical testing, the compound also demonstrated an ability to effectively cross the blood brain barrier, and demonstrated an ability to extend survival in an intracranial glioblastoma model. Early stage toxicity studies suggest that CUDC-305 appears to have a better therapeutic window than several leading Hsp90 inhibitors in clinical development.
Status:
Investigational
Source:
NCT01697930: Phase 1 Interventional Recruiting Solid Malignancy
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01815515: Phase 1/Phase 2 Interventional Completed Metastatic Prostate Cancer
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02315352: Phase 1 Interventional Completed Healthy
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Praziquantel, (-)- is oxopyrazinoisoquinoline derivative and a levorotated isomer of Praziquantel patented by Merck Patent G.m.b.H. as anthelmintics agent. In rabbits infested with S. japonicum, the therapeutic effect of Praziquantel, (-)-was greater than that of dl-praziquantel as rated by the number of the worms in tissues and by liver damage. Histopathological examination showed that liver egg granulomas in the levo-praziquantel group were fewer in no. and smaller in size and were predominantly composed of Pseudotubercles instead of eosinophilic abscesses. Levo-praziquantel is therapeutically superior to praziquantel, while dextro-praziquantel is almost ineffective.
Status:
Investigational
Source:
NCT01782664: Phase 2 Interventional Completed Psoriasis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Solcitinib (also known as GSK2586184 or GLPG0778) is a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of psoriasis, lupus, and ulcerative colitis. Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. It was reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect. And an exploratory Phase I/II of the same drug for ulcerative colitis was put on hold as investigators review the program.
Status:
Investigational
Source:
NCT00002452: Phase 2 Interventional Completed HIV Infections
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:mirivadelgat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
Eur Respir J. Jan 2004;23(1):76-81.: Not Applicable Human clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03786380: Phase 3 Interventional Terminated Gastroparesis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Relamorelin (also known as BIM28131 or RM-131) is a synthetic, selective, prokinetic ghrelin analog that was developed for treatment of gastrointestinal motility disorders (such as chronic constipation and diabetic gastroparesis). Relamorelin was shown to relief symptoms such as nausea, fullness, bloating and abdominal pain. It is safe and well-tolerated in healthy individuals, and has no neurological or cardiovascular adverse effects, making this a promising drug with an advantage over other available therapies. A phase III clinical trial comparing the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) was still ongoing in 2019.
